Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katsuyuki Hotta

Showing results (1-10 of 286) with videos related to

Pageof 29
Sort By:
Critical Reviews in Oncology/Hematology|June 2, 2005
New cytotoxic agents: a review of the literatureKatsuyuki Hotta, Hiroshi Ueoka
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 19, 2011
[Neoplastic meningitis]Katsuyuki Hotta, Mitsune Tanimoto
Expert Review of Anticancer Therapy|August 3, 2011
Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancerKatsuyuki Hotta, Katsuyuki Kiura
Expert Opinion on Biological Therapy|September 13, 2018
Pembrolizumab for the first-line treatment of non-small cell lung cancerKiichiro Ninomiya, Katsuyuki Hotta
Journal for Immunotherapy of Cancer|February 27, 2020
Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesotheliomaKatsuyuki Hotta, Nobukazu Fujimoto
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small cell lung cancerKatsuyuki Hotta, Keitaro Matsuo
Respiratory Investigation|April 20, 2019
Recent trends in the treatment of unresectable stage III non-small-cell lung cancerGo Makimoto, Katsuyuki Hotta, Katsuyuki Kiura
Lung Cancer (Amsterdam, Netherlands)|June 15, 2005
Toxicity data in addition to survival data are important in evaluating the applicability of a chemotherapy regimen of advanced non-small-cell lung cancerKatsuyuki Hotta, Keitaro Matsuo, Hiroshi Ueoka
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 23, 2015
Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients with Non-Small-Cell Lung CancerEiki Ichihara, Katsuyuki Hotta, Katsuyuki Kiura
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2005
They also serve who only stand and wait: do individual clinical researchers, too? Hoping for individual patient data as public domainKeitaro Matsuo, Katsuyuki Hotta, Hiroshi Ueoka
Pageof 29

Showing results (1-10 of 286) with videos related to

Sort By:
Pageof 29
Critical Reviews in Oncology/Hematology|June 2, 2005
New cytotoxic agents: a review of the literatureKatsuyuki Hotta, Hiroshi Ueoka
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 19, 2011
[Neoplastic meningitis]Katsuyuki Hotta, Mitsune Tanimoto
Expert Review of Anticancer Therapy|August 3, 2011
Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancerKatsuyuki Hotta, Katsuyuki Kiura
Expert Opinion on Biological Therapy|September 13, 2018
Pembrolizumab for the first-line treatment of non-small cell lung cancerKiichiro Ninomiya, Katsuyuki Hotta
Journal for Immunotherapy of Cancer|February 27, 2020
Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesotheliomaKatsuyuki Hotta, Nobukazu Fujimoto
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small cell lung cancerKatsuyuki Hotta, Keitaro Matsuo
Respiratory Investigation|April 20, 2019
Recent trends in the treatment of unresectable stage III non-small-cell lung cancerGo Makimoto, Katsuyuki Hotta, Katsuyuki Kiura
Lung Cancer (Amsterdam, Netherlands)|June 15, 2005
Toxicity data in addition to survival data are important in evaluating the applicability of a chemotherapy regimen of advanced non-small-cell lung cancerKatsuyuki Hotta, Keitaro Matsuo, Hiroshi Ueoka
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 23, 2015
Challenges in Bevacizumab and Gefitinib Combination Therapy for Patients with Non-Small-Cell Lung CancerEiki Ichihara, Katsuyuki Hotta, Katsuyuki Kiura
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 19, 2005
They also serve who only stand and wait: do individual clinical researchers, too? Hoping for individual patient data as public domainKeitaro Matsuo, Katsuyuki Hotta, Hiroshi Ueoka
Pageof 29